Le Lézard
Classified in: Health
Subject: TRI

Genetic Treatment for Blindness May Soon be Reality



NEW ORLEANS, Nov. 10, 2017 /PRNewswire-USNewswire/ -- Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.

AAO Logo (PRNewsFoto/American Academy of Ophthalmology)

Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its-kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.

Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.

Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.

LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient's eyes.

Treatment doesn't restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.

More than 200 patients with LCA have participated in gene therapy trials since 2007.
However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn't obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.

About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world's largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit aao.org.

SOURCE American Academy of Ophthalmology


These press releases may also interest you

at 18:16
In an attempt to improve patient care for people with kidney failure and lower healthcare costs in California, the country's largest public pension fund today endorsed a statewide initiative that qualified for the Nov. 6 ballot. A CalPERS staff...

at 17:59
Invesque announced today a cash dividend in the amount of US$.06139 per common share for the period from June 1, 2018 to June 30, 2018. The dividend will be payable on July 15, 2018 to shareholders of record as of June 30, 2018. About...

at 17:57
"Today's executive order appears to have suspended parent and child separation at our southern borders, and it is important that families are reunited quickly.  This situation continues to result in unnecessary trauma being inflicted on children. As...

at 17:30
The "Radiation Cured Products - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and...

at 17:19
The Lanier Law Firm has announced that proceeds from this year's Lanier Trial Academy will once again benefit Guatemala SANA Children's Project, a nonprofit that provides health care and education services to children in Guatemala. Now in its third...

at 17:16
A researcher from LA BioMed has been awarded $688,013 in grant funding from the National Institutes of Health to improve newborn infant screening. The proposal by Rie Sakai-Bizmark, MD, PhD, MPH is entitled "Newborn Screening for Critical Congenital...




News published on 10 november 2017 at 18:11 and distributed by: